Drug Profile
Pemetrexed - Eli Lilly and Company
Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multitargeted antifolate; Pemetrexed disodiumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly; Eli Lilly and Company; John Wayne Cancer Institute; Merck Sharp & Dohme; University of California, Davis; Virginia Commonwealth University
- Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mesothelioma; Non-small cell lung cancer
- Phase II Breast cancer
- Phase I/II Solid tumours
- No development reported Chordoma; Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
- Discontinued Small cell lung cancer
Most Recent Events
- 29 Jun 2023 Efficacy and adverse events data from a phase III KEYNOTE-671 trial in Non-small cell lung cancer released by MSD Pharmaceuticals
- 22 Jun 2023 Merck completes the phase III KEYNOTE-189 trial for Non small cell lung cancer (First line therapy, Combination therapy) in in Ireland, Germany, the UK, Austria, Belgium, Spain, the Netherlands, Finland, Japan and Denmark (NCT02578680) (JapicCTI163421) (EudraCT2015-003694-15)
- 18 Jan 2023 Eli Lilly and Company and Saint John's Cancer Institute completes a phase-I clinical trial in Chordoma in USA (IV) (NCT03955042)